A Strategy to Model Nonmonotonic Dose-Response Curve and Estimate IC50

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Zhang, Hui ^a   Holden Wiltse, Jeanne ^b   Wang, Jiong ^b   Liang, Hua ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CALCULATION; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; IC 50; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NONPARAMETRIC TEST; SIMULATION; STATISTICAL SIGNIFICANCE;

ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV; INHIBITORY CONCENTRATION 50; MODELS, STATISTICAL; MUTATION; STATISTICS, NONPARAMETRIC;

EID: 84880974916     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069301     Document Type: Article

References (27)

1. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, et al. (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New England Journal of Medicine 341: 1865-1873.
2. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, et al. (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. New England Journal of Medicine 349: 2293-2303.
3. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, et al. (2004) Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. New England Journal of Medicine 350: 1850-1861.
4. Domaoal RA, Bambara RA, Demeter LM, (2006) HIV-1 reverse transcriptase mutants resistant to nonnucleoside reverse transcriptase inhibitors do not adversely affect DNA synthesis: pre-steady-state and steady-state kinetic studies. Journal of Acquired Immune Deficiency Syndromes 42: 405-411.
5. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, et al. (2001) Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse tran-scriptase inhibitor therapy. Journal of Virology 75: 4999-5008.
6. Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, et al. (2000) Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrobial Agents and Chemotherapy 44: 2475-2484.
7. Koval CE, Dykes C, Wang J, Demeter LM, (2006) Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N+ L100I by the nucleoside resistance mutation L74V. Virology 353: 184-192.
8. Prentice RL, (1976) A generalization of the probit and logit methods for dose response curves. Biometrics 32: 761-768.
9. Bliss C, (1941) Statistical problems in estimating populations of Japanese beetle larvae. Journal of Economic Entomology 34: 221-232.
10. Huang W, Parkin N, Lie Y, Wrin T, Haubrich R, et al. (2000) A novel HIV-1 RT mutation (M230L) confers NNRTI resistance and dose-dependent stimulation of replication. Antiviral Therapy 5: 24-25.
11. Wang J, Liang H, Bacheler L, Wu H, Deriziotis K, et al. (2010) The non-nucleoside reverse transcrip-tase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations. Virology 402: 228-237.
12. Ramsay J, (1988) Monotone regression splines in action. Statistical Science 3: 425-441.
13. Bowman A, Jones M, Gijbels I, (1998) Testing monotonicity of regression. Journal of Computational and Graphical Statistics 7: 489-500.
14. Hall P, Heckman NE, (2000) Testing for monotonicity of a regression mean by calibrating for linear functions. Annals of Statistics 28: 20-39.
15. Fan J, Gijbels I (1996) Local Polynomial Modelling And Its Applications, volume 66. Chapman & Hall/CRC.
16. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, et al. (2007) Non-parametric quanti_cation of protein lysate arrays. Bioinformatics 23: 1986-1994.
17. Calabrese EJ, Baldwin LA, (1998) Hormesis as a biological hypothesis. Environmental Health Perspectives 106: 357-362.
18. Sagan LA, (1987) What is hormesis and why haven't we heard about it before. Health Physics 52: 521-525.
19. Stebbing A, (1982) Hormesisthe stimulation of growth by low levels of inhibitors. Science of the Total Environment 22: 213-234.
20. Davis JM, Svendsgaard DJ, (1990) U-shaped dose-response curves: Their occurrence and implica-tions for risk assessment. Journal of Toxicology and Environmental Health, Part A 30: 71-83.
21. Prest SJ, May FE, Westley BR, (2002) The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. The FASEB Journal 16: 592-594.
22. Visnjić D, Batinić D, Banfić H, (1999) Di_erent roles of protein kinase c alpha and delta isoforms in the regulation of neutral sphingomyelinase activity in HL-60 cells. Biochemical Journal 344: 921-928.
23. Poland GA, Jacobson RM, Koutsky LA, Tamms GM, Railkar R, et al. (2005) Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. In: Mayo Clinic Proceedings. Elsevier, volume 80, 601-610.
24. Masuda K, Yokomizo T, Izumi T, Shimizu T, (1999) cDNA cloning and characterization of guinea-pig leukotriene B4 receptor. Biochemical Journal 342: 79-85.
25. Kohn MC, (1995) Biochemical mechanisms and cancer risk assessment models for dioxin. Toxicology 102: 133-138.
26. Gibbs B, Rathling A, Zillikens D, Huber M, Haas H, (2006) Initial Fc epsilon RI-mediated signal strength plays a key role in regulating basophil signaling and deactivation. Journal of Allergy and Clinical Immunology 118: 1060-1067.
27. Gallicchio M, Rosa AC, Benetti E, Collino M, Dianzani C, et al. (2006) Substance p-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells. British Journal of Pharma-cology 147: 681-689.